GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pacific Edge Ltd (ASX:PEB) » Definitions » EV-to-EBITDA

Pacific Edge (ASX:PEB) EV-to-EBITDA : -0.98 (As of Jun. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pacific Edge EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pacific Edge's enterprise value is A$30.70 Mil. Pacific Edge's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was A$-31.48 Mil. Therefore, Pacific Edge's EV-to-EBITDA for today is -0.98.

The historical rank and industry rank for Pacific Edge's EV-to-EBITDA or its related term are showing as below:

ASX:PEB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -66.09   Med: -9.14   Max: 0.67
Current: -0.97

During the past 13 years, the highest EV-to-EBITDA of Pacific Edge was 0.67. The lowest was -66.09. And the median was -9.14.

ASX:PEB's EV-to-EBITDA is ranked worse than
100% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 15.58 vs ASX:PEB: -0.97

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-16), Pacific Edge's stock price is A$0.082. Pacific Edge's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was A$-0.034. Therefore, Pacific Edge's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Pacific Edge EV-to-EBITDA Historical Data

The historical data trend for Pacific Edge's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Edge EV-to-EBITDA Chart

Pacific Edge Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.89 -43.20 -28.41 -7.61 -0.66

Pacific Edge Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.41 - -7.61 - -0.66

Competitive Comparison of Pacific Edge's EV-to-EBITDA

For the Diagnostics & Research subindustry, Pacific Edge's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Edge's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pacific Edge's EV-to-EBITDA falls into.



Pacific Edge EV-to-EBITDA Calculation

Pacific Edge's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=30.702/-31.484
=-0.98

Pacific Edge's current Enterprise Value is A$30.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pacific Edge's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was A$-31.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pacific Edge  (ASX:PEB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pacific Edge's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.082/-0.034
=At Loss

Pacific Edge's share price for today is A$0.082.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pacific Edge's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was A$-0.034.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Pacific Edge EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pacific Edge's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacific Edge (ASX:PEB) Business Description

Traded in Other Exchanges
Address
87 St David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.